首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1861046

TIGIT抑制劑市場:臨床試驗與市場機會預測(2026年)

Global TIGIT Inhibitors Drugs Clinical Trials & Market Opportunity Outlook 2026

出版日期: 2025年11月01日 | 出版商:

KuicK Research | 英文 160 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

TIGIT抑制劑市場：臨床試驗及市場機會展望（2026）報告結果及亮點

預計首個TIGIT抑制劑將於2030年核准
正在進行臨床試驗的TIGIT抑制劑：超過40種藥物
按公司、適應症和階段劃分的全球TIGIT抑制劑臨床研發管線概覽
超過40種正在進行臨床試驗的TIGIT抑制劑概覽
全球TIGIT抑制劑市場動態
競爭格局

TIGIT抑制劑的需求及本報告的意義

隨著人們對TIGIT在免疫逃脫中的作用及其增強癌症免疫療法的潛力的認識不斷加深，TIGIT抑制劑市場正在迅速發展。本報告分析了不斷擴展的TIGIT抑制劑領域，並全面展望了這一極具前景的治療類別的最新科學進展、臨床試驗和未來商業前景。儘管許多癌症對現有療法存在抗藥性，但抑制免疫檢查點的新方法的需求日益增長，使得TIGIT抑制劑的研發成為當務之急。

本報告追蹤該領域的最新進展，並提供關鍵見解，幫助投資者、研究人員和臨床醫生在這個高風險、高回報的市場中把握機會。透過檢視臨床潛力和商業機會，本報告強調了TIGIT抑制劑在更廣泛的癌症領域中的策略意義，並突顯了其在癌症治療中日益增長的重要性。

本報告包含的臨床研究和臨床試驗資訊

本報告全面深入分析了TIGIT標靶抑制劑的主要臨床試驗，提供了不同適應症、試驗申辦者、地區和研發階段的寶貴數據。 TIGIT抑制劑推動了臨床研發管線的發展，但了解其在特定癌症中的潛力至關重要。TIGIT抑制劑的臨床試驗正在測試其在多種實體腫瘤中的療效，包括非小細胞肺癌、胃癌和黑色素瘤。正在進行的試驗將TIGIT抑制劑與PD-1/PD-L1抑制劑、化療和其他免疫療法合併使用，以增強抗腫瘤免疫反應。

本報告也詳細介紹了試驗申辦方，包括大型製藥公司和新興生技公司，有助於展現推動該領域創新發展的利害關係人。從地理上看，這些臨床試驗正在北美、歐洲和亞洲進行，體現了全球參與，反映了人們對TIGIT抑制劑治療潛力的廣泛興趣。因此，本部分對於需要掌握臨床開發進展的學術研究人員以及商業決策者來說都是重要的參考資料。

參與TIGIT抑制劑研發的主要公司

本報告詳細回顧了積極從事TIGIT抑制劑研發的主要公司，包括羅氏、吉利德科學和默克等製藥公司，以及Arcus Biosciences、Compugen和Vir Biotechnology等創新生物技術公司。領先的TIGIT抑制劑研發公司目前擁有豐富的研發管線，針對多種癌症適應症。主要製藥公司正在評估單藥療法和與PD-1/PD-L1抑制劑聯合的療法，以增強免疫反應。本報告重點在於這些公司的研究方法和臨床進展，為利害關係人清晰展現競爭格局。

展望TIGIT抑制劑領域未來發展方向的報告

本報告展望了TIGIT抑制劑在癌症免疫治療領域的未來發展前景。儘管臨床試驗持續產生令人鼓舞的數據，但TIGIT抑制劑很可能發揮越來越重要的作用，尤其是在聯合治療方案中，這些方案可以克服目前常用療法（例如PD-1/PD-L1抑制劑）的限制。 TIGIT抑制劑能夠增強對其他免疫檢查點抑制劑抗藥性的腫瘤的免疫反應，代表著癌症領域中尚未滿足醫療需求的重要治療途徑。此外，目前正在積極研究預測患者對TIGIT抑制劑反應的生物標記物，這有望實現個別化治療並改善臨床療效。

本報告預測，未來將有更多TIGIT抑制劑上市，重點是與其他免疫療法、化療甚至放射療法合併使用。隨著更多臨床試驗數據的出現，TIGIT抑制劑成為癌症免疫療法基石的潛力日益凸顯，這將為患者帶來希望，並為所有投資於此快速發展領域的投資者帶來機會。

First TIGIT Inhibitor Drug Approval Expected By 2030
TIGIT Inhibitors Drugs In Clinical Trials: > 40 Drugs
Global TIGIT Inhibitors Drugs Clinical Pipeline Insight By Company, Indication and Phase
Insight On More Than 40 TIGIT Inhibitors Drugs In Clinical Trials
Global TIGIT Inhibitors Drugs Market Dynamics
Competitive Landscape

TIGIT Inhibitors Need & Why This Report?

The market for TIGIT inhibitors is rapidly evolving, with growing recognition of the role of TIGIT in immune evasion and its potential to enhance cancer immunotherapy. This report provides an essential analysis of the expanding TIGIT inhibitor landscape, offering a comprehensive overview of recent scientific advances, clinical trials, and the future commercial prospects of this promising therapeutic class. While many cancers remain resistant to current treatments, a growing need exists for the development of new ways to inhibit immune checkpoints, making the development of TIGIT inhibitors of highest importance.

This report tracks developments currently taking place within the sector, providing key insights for investors, researchers, and clinicians are navigating this high risk, high reward market. By examining both the clinical potential and commercial opportunities, this report highlights the strategic relevance of TIGIT inhibitors in the broader oncology field and underlines their growing importance for the treatment of cancer.

Clinical Studies & Trials Insight Included In Report

The report provides comprehensive insight into main clinical trials of the inhibitors targeting TIGIT, offering valued data on different indications, trial sponsors, geographical regions, and phases of development. While TIGIT inhibitors progress through the clinical pipeline, it becomes paramount to understand their potential in certain cancers. Clinical trials for TIGIT inhibitors are testing the inhibitor's efficacy in different solid tumors such as NSCLC, gastric cancer, melanoma, and many more. Trials are underway to study a combination of TIGIT inhibitors with PD-1/PD-L1 inhibitors, chemotherapy, and other immunotherapies for improving anti-tumor immune responses.

The report also details trial sponsors, including big pharmaceutical players and emerging biotech, which helps paint a picture of the stakeholders involved in driving innovation in this space. From a geographical perspective, these trials are ongoing across North America, Europe, and Asia, with global participation reflecting widespread interest in the therapeutic potential of TIGIT inhibition. This section therefore is an important tool for commercial decision makers as well as academic researchers who need to keep up to date with the momentum within the clinical development landscape.

Leading Companies Engaged In R&D Of TIGIT Inhibitors

The report provides an in-depth review of the major companies actively pursuing research and development activities for TIGIT inhibitors, whether pharmaceutical companies such as Roche, Gilead Sciences, and Merck or innovative biotech firms including Arcus Biosciences, Compugen, and Vir Biotechnology. Leading developers of TIGIT inhibitors are currently working with deep pipelines targeting multiple cancer indications. Large pharma companies are evaluating monotherapies and combinations, often in association with PD-1/PD-L1 inhibitors to enhance immune responses. It highlights the research approaches and clinical development for such companies and provides a clear picture of the competitive landscape to stakeholders.

Report Indicating Future Direction Of TIGIT Inhibitors Segment

This report looks ahead to the future of the TIGIT inhibitors segment in cancer immunotherapy. While clinical trials continue to churn out encouraging data, TIGIT inhibitors will increasingly take center stage, especially in combination regimens that can obviate limitations seen with currently deployed approaches such as PD-1/PD-L1 inhibitors. The ability of TIGIT inhibitors to enhance immune responses in tumors resistant to other immune checkpoint inhibitors makes the drugs a key therapeutic modality in cancers with unmet needs. Furthermore, active research into biomarkers predictive of patient response to TIGIT inhibition may allow for tailored treatments and improvement in clinical outcome.

The report predicts that more TIGIT inhibitors will enter the market, with a strong emphasis on their combination with other immunotherapies, chemotherapy, and even radiation therapy. As more data is unveiled from clinical trials, the potential for TIGIT inhibitors to become a cornerstone in cancer immunotherapy becomes much more real, bringing hope to patients and opportunities to all those invested in this burgeoning segment.

1. Introduction To TIGIT Inhibitors

1.1 Overview
1.2 Mechanistic Insights Into TIGIT Inhibitor Function
1.3 Clinical Strategies For Targeting TIGIT

2. Global TIGIT Inhibitors Clinical Trials Overview

2.1 By Company
2.2 By Country
2.3 By Indication
2.4 By Phase

3. Global TIGIT Inhibitors Clinical Pipeline By Company, Indication and Phase

3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase III

4. Global TIGIT Inhibitors Market Outlook

4.1 Current Clinical & Market Trends
4.2 Future Market Opportunities

5. TIGIT Inhibitors Market Trends by Indication

5.1 Cancer
5.2 Autoimmune & Inflammatory Disorders
5.3 Microbial Infections

6. TIGIT Inhibitors Market Trends By Region

6.1 US
6.2 China
6.3 South Korea
6.4 Australia
6.5 Europe

7. Integrating TIGIT Inhibition With Other Therapeutic Modalities

8. Dual Checkpoint Blockade - TIGIT With PD-1/PD-L1

9. Global TIGIT Inhibitors Market Dynamics

9.1 Market Drivers & Opportunities
9.2 Commercialization Challenges & Solutions

10. Competitive Landscape

10.1 Akeso Biopharma
10.2 AstraZeneca
10.3 BeOne Medicines
10.4 Bio-Thera Solutions
10.5 BioNTech
10.6 Compugen
10.7 FutureGen Biopharmaceutical
10.8 Merck & Co / MSD
10.9 Nanjing Sanhome Pharmaceutical
10.10 OriCell Therapeutics
10.11 Phio Pharmaceuticals
10.12 Roche
10.13 Shanghai Henlius Biotech
10.14 Shanghai Junshi Biosciences
10.15 Simcere Pharmaceutical Group

簡介目錄圖表

List of Figures

Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 1-2: TIGIT Inhibitors - Proposed Mechanism of Action
Figure 1-3: TIGIT Inhibitor - Mechanism Of Action
Figure 1-4: Monoclonal Antibody - Binding Efficacy
Figure 1-5: Bispecific Antibodies - Binding Efficacy
Figure 1-6: Small Molecule Drugs - Advantages
Figure 2-1: Global - TIGIT Inhibitors Clinical Trials by Company (Number of Drugs), 2026
Figure 2-2: Global - TIGIT Inhibitors Clinical Trials by Country (Number of Drugs), 2026
Figure 2-3: Global - TIGIT Inhibitors Clinical Trials by Indication (Number of Drugs), 2026
Figure 2-4: Global - TIGIT Inhibitors Clinical Trials by Phase (Number of Drugs), 2026
Figure 4-1: Global TIGIT Inhibitors Market - Future Market Opportunities
Figure 5-1: TIGIT - Impact On Tumor Microenvironment
Figure 5-2: TIGIT In Cancer Immune Escape
Figure 5-3: PACIFIC-8 Phase 3 (NCT05211895) Study - Initiation & Completion Year
Figure 5-4: STAR-221 Phase 3 (NCT05568095) Study - Initiation & Completion Year
Figure 5-5: STAR-121 Phase 3 (NCT05502237) Study - Initiation & Completion Year
Figure 5-6: Rilvegostomig - Ongoing Phase 3 Clinical Trials
Figure 5-7: TIGIT Mechanisms In Tregs
Figure 5-8: Microbial Infections - TIGIT Signaling & Immune Suppression
Figure 5-9: Microbial Infections - Therapeutic Targeting Of TIGIT
Figure 7-1: TIGIT Therapy Combinations
Figure 7-2: TIGIT Inhibitor Combination Trials
Figure 9-1: Global TIGIT Inhibitors Market - Drivers & Opportunities
Figure 9-2: Global TIGIT Inhibitors Market - Commercialization Challenges & Solutions